IDEXX Laboratories, Inc. (IDXX) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
IDXX price how computed
Forward Fair Value verdict
UndervaluedIDXX is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $518.00
- Sector
- Healthcare
- 12-month range
- $504.70–$766.68
- Market cap
- $40.9B
- From 52-week high
- -32.4%
- Shares outstanding
- 78.9M
- Rank in Healthcare by discount to fair value
- #19 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
IDEXX Laboratories, Inc. manufactures and distributes diagnostic equipment, software, and consumables for veterinary, water, and dairy testing purposes. The company operates globally with a presence in multiple countries across North America, Europe, Asia, and other international markets.
IDXX currently ranks #19 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $40.9B
- P/E (trailing)
- 36x
- Revenue (TTM)
- $4.55B
- Net margin
- 25.0%
- EPS (TTM)
- $14.22
- Gross margin
- 64.0%
- Debt / equity
- 0.68
- Revenue growth (3-yr avg)
- 11.0%
- Shares outstanding
- 78.9M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 72 · overbought
- 50-day average
- $535.25
- 200-day average
- $579.67
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-02 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+8.1%)
2026-03 ▲ beat (+1.8%)
2025-12 ▲ beat (+4.8%)
2025-09 ▲ beat (+7.9%)
2025-06 ▲ beat (+10.0%)
2025-03 ▲ beat (+4.2%)
2024-12 ▲ beat (+9.2%)
2024-09 ▲ beat (+4.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 4 hold · 1 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $706
- Target vs last price
- +36.3%
What our data shows for IDXX
- Our model validated 17 trailing price-to-earnings windows for IDXX, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $504.70–$766.68.
- The 14-day relative strength index sits at an overbought 72.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for IDXX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent IDXX news
TickrTrends' derived news-sentiment signal for IDXX is currently leaning positive, computed from recent coverage.
- IDEXX Laboratories Inc (IDXX): GF Score of 96 Signals Strong Outperformance Potential (gurufocus.com, 2026-10-19)
TickrTrends take: IDEXX Laboratories operates in the Healthcare sector and currently carries an Undervalued designation from TickrTrends valuation analysis. The GF Score of 96 reported in recent analysis suggests the company demonstrates strong fundamental characteristics that align with this undervaluation assessment. Investors focused on valuation metrics should monitor whether this combination of high quality indicators and undervalued pricing conditions persists as market conditions evolve. - IDXX Maintains Overweight Rating with JP Morgan -- Price Target Lowered to $750 (gurufocus.com, 2026-10-16)
TickrTrends take: JP Morgan's maintenance of an overweight rating on IDXX while lowering its price target to $750 suggests analyst confidence in the company's fundamentals despite near-term headwinds or valuation adjustments. This action occurs within a context where TickrTrends currently identifies IDXX as undervalued, indicating potential misalignment between the market's current pricing and the company's intrinsic worth as measured by valuation metrics. Investors focused on valuation should monitor whether the revised price target influences the gap between current market price and IDXX's assessed fair value, particularly given the company's position in the Healthcare sector. - IDEXX Laboratories Inc (IDXX): GF Score of 96 Signals Strong Outperformance Potential (gurufocus.com, 2026-10-16)
TickrTrends take: IDEXX Laboratories trades at valuations the TickrTrends model currently identifies as undervalued, while the company's GF Score of 96 suggests strong fundamental quality metrics that typically correlate with outperformance. For valuation-focused investors, this combination of low relative valuation and high-quality fundamentals presents the type of setup that historically has preceded meaningful price appreciation in healthcare sector stocks. Monitoring whether the market begins to re-rate IDEXX's valuation closer to its quality profile would be a key focal point for tracking the thesis.
More IDXX news
- IDEXX Laboratories Inc (IDXX) Shares Surge 3.4% -- What GF Score of 96 Tells Investors (gurufocus.com, 2026-10-15)
- IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets (finance.yahoo.com, 2026-09-20)
- IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics (insidermonkey.com, 2026-09-19)
- Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink? (finance.yahoo.com, 2026-08-26)
What people are saying
Follow the IDXX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — IDXX moved into overbought territory this week as its RSI indicator crossed into that zone, shifting from a neutral reading in the prior week. The stock remains classified as undervalued based on current valuation metrics within the Healthcare sector. This combination of overbought momentum alongside an undervalued fundamental assessment suggests the stock is experiencing near-term strength while maintaining longer-term value characteristics.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — IDXX has moved from an oversold RSI zone to a neutral zone this week, indicating a shift in momentum conditions. The stock maintains an undervalued assessment according to current valuation metrics within the Healthcare sector.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is IDXX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), IDXX is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is IDXX's TickrTrends verdict?
IDXX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does IDXX compare to other Healthcare stocks?
IDXX ranks #19 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is IDXX overbought or oversold?
IDXX's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
When does IDXX report earnings next?
IDXX's next earnings report is scheduled for 2026-11-02 (pre-market), per the published earnings calendar.
Does IDXX usually beat earnings estimates?
Over its last 8 reported quarters IDXX beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about IDXX?
Of 13 analysts covering IDXX, 8 rate it a buy, 4 a hold and 1 a sell - buy-leaning, with a consensus price target of $706 (+36.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
IDXX vs GEHC · IDXX vs INCY · IDXX vs INDV · IDXX vs ISRG · IDXX vs PGNY